The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...